To read the full story
Related Article
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- JCR to Focus on Partnerships as Core of Growth Strategy: Vice President
March 30, 2022
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- JCR Hooks Up with Takeda on Global Expansion of Hunter Syndrome Drug
October 1, 2021
BUSINESS
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
- Toho Backs AI Startup Developing Laxative-Free Colonoscopy
November 16, 2026
- KM Biologics Files Japan’s Potential First Therapy for Factor X Deficiency
November 16, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





